770 related articles for article (PubMed ID: 17916095)
1. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions.
Shield PW; Koivurinne K
Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095
[TBL] [Abstract][Full Text] [Related]
2. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
3. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion].
Su XY; Li GD; Liu HB; Jiang LL
Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932
[TBL] [Abstract][Full Text] [Related]
4. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
5. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
6. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
7. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks.
Kim JH; Kim GE; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Diagn Cytopathol; 2009 Apr; 37(4):258-61. PubMed ID: 19217030
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
Wieczorek TJ; Krane JF
Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
[TBL] [Abstract][Full Text] [Related]
11. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
Ordóñez NG
Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
[TBL] [Abstract][Full Text] [Related]
12. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
[TBL] [Abstract][Full Text] [Related]
13. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary.
Comin CE; Saieva C; Messerini L
Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535
[TBL] [Abstract][Full Text] [Related]
14. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions.
Zhu W; Michael CW
Diagn Cytopathol; 2007 Jun; 35(6):370-5. PubMed ID: 17497661
[TBL] [Abstract][Full Text] [Related]
15. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
16. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
18. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma.
Kushitani K; Takeshima Y; Amatya VJ; Furonaka O; Sakatani A; Inai K
Pathol Int; 2007 Apr; 57(4):190-9. PubMed ID: 17316414
[TBL] [Abstract][Full Text] [Related]
20. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
